This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Grace McComsey, National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00433992
First received: February 9, 2007
Last updated: June 16, 2017
Last verified: June 2017
Results First Received: March 28, 2017  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: HIV Infections

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ABC/3TC HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)
TDF/FTC HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)

Participant Flow:   Overall Study
    ABC/3TC   TDF/FTC
STARTED   28   28 
COMPLETED   19   20 
NOT COMPLETED   9   8 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ABC/3TC HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)
TDF/FTC HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)
Total Total of all reporting groups

Baseline Measures
   ABC/3TC   TDF/FTC   Total 
Overall Participants Analyzed 
[Units: Participants]
 28   28   56 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      28 100.0%      28 100.0%      56 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      3  10.7%      4  14.3%      7  12.5% 
Male      25  89.3%      24  85.7%      49  87.5% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      0   0.0%      0   0.0%      0   0.0% 
Asian      0   0.0%      0   0.0%      0   0.0% 
Native Hawaiian or Other Pacific Islander      0   0.0%      0   0.0%      0   0.0% 
Black or African American      8  28.6%      4  14.3%      12  21.4% 
White      10  35.7%      12  42.9%      22  39.3% 
More than one race      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      10  35.7%      12  42.9%      22  39.3% 


  Outcome Measures

1.  Primary:   Change in Mitochondrial Activity   [ Time Frame: Entry, Week 96 ]

2.  Secondary:   Change in Fat Apoptosis   [ Time Frame: Entry, Week 96 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Limitations included small sample size and premature study discontinuation before week 96


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Grace McComsey
Organization: Case Western Reserve University
phone: 216-844-2739
e-mail: mccomsey.grace@clevelandactu.org



Responsible Party: Grace McComsey, National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00433992     History of Changes
Other Study ID Numbers: 1R01AI065348-01A2 ( U.S. NIH Grant/Contract )
Study First Received: February 9, 2007
Results First Received: March 28, 2017
Last Updated: June 16, 2017